These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

45 related items for PubMed ID: 21219119

  • 21. Exenatide and pramlintide: new therapies for diabetes.
    Want LL, Ratner R.
    Int J Clin Pract; 2006 Dec; 60(12):1522-3. PubMed ID: 17109659
    [No Abstract] [Full Text] [Related]

  • 22. Exenatide-a potential role in treatment of HNF1-alpha MODY in obese patients?
    Ahluwalia R, Perkins K, Ewins D, Goenka N.
    Diabet Med; 2009 Aug; 26(8):834-5. PubMed ID: 19709161
    [No Abstract] [Full Text] [Related]

  • 23. Multilayer nanoparticles for sustained delivery of exenatide to treat type 2 diabetes mellitus.
    Kim JY, Lee H, Oh KS, Kweon S, Jeon OC, Byun Y, Kim K, Kwon IC, Kim SY, Yuk SH.
    Biomaterials; 2013 Nov; 34(33):8444-9. PubMed ID: 23895999
    [Abstract] [Full Text] [Related]

  • 24. Exenatide in acute ischemic stroke.
    Daly SC, Chemmanam T, Loh PS, Gilligan A, Dear AE, Simpson RW, Bladin CF.
    Int J Stroke; 2013 Oct; 8(7):E44. PubMed ID: 24024920
    [No Abstract] [Full Text] [Related]

  • 25. Mapping Census Tract Clusters of Type 2 Diabetes in a Primary Care Population.
    Kolak M, Abraham G, Talen MR.
    Prev Chronic Dis; 2019 May 16; 16():E59. PubMed ID: 31095922
    [No Abstract] [Full Text] [Related]

  • 26. Real-world data from first UK Omnipod 5 users: A single-centre observational study.
    Aslam A, Chapman A, Urwin A, Ohol S, Thomas S, Gough R, Findlow LA, Lim J, Schofield J, Leelarathna L, Thabit H.
    Diabetes Obes Metab; 2024 Aug 16; 26(8):3462-3465. PubMed ID: 38698652
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.
    Mathieu C, Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljański J, Salaun-Martin C, Sapin H, Theodorakis M.
    Diabetes Ther; 2013 Dec 16; 4(2):285-308. PubMed ID: 24018835
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting.
    Bergenstal RM, Garrison LP, Wintle M, Blickensderfer A, Wade R, Hou L, Miller LA, Scism-Bacon J, Zagar A, Misurski D, Herman WH.
    Curr Med Res Opin; 2011 Mar 16; 27(3):531-40. PubMed ID: 21219119
    [Abstract] [Full Text] [Related]

  • 31. Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting.
    Pawaskar M, Li Q, Reynolds MW.
    Curr Med Res Opin; 2012 Jun 16; 28(6):991-7. PubMed ID: 22519390
    [Abstract] [Full Text] [Related]

  • 32. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JH.
    Clin Ther; 2008 May 16; 30(5):858-67. PubMed ID: 18555933
    [Abstract] [Full Text] [Related]

  • 33. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series.
    Kenny PR, Brady DE, Torres DM, Ragozzino L, Chalasani N, Harrison SA.
    Am J Gastroenterol; 2010 Dec 16; 105(12):2707-9. PubMed ID: 21131943
    [No Abstract] [Full Text] [Related]

  • 34. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B.
    Int J Clin Pract; 2006 Dec 16; 60(12):1654-61. PubMed ID: 17109672
    [Abstract] [Full Text] [Related]

  • 35. Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting.
    Bergenstal RM, Garrison LP, Wintle M, Blickensderfer A, Wade R, Hou L, Miller LA, Scism-Bacon J, Zagar A, Misurski D, Herman WH.
    Curr Med Res Opin; 2011 Mar 16; 27(3):531-40. PubMed ID: 21219119
    [Abstract] [Full Text] [Related]

  • 36. Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting.
    Pawaskar M, Li Q, Reynolds MW.
    Curr Med Res Opin; 2012 Jun 16; 28(6):991-7. PubMed ID: 22519390
    [Abstract] [Full Text] [Related]

  • 37. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JH.
    Clin Ther; 2008 May 16; 30(5):858-67. PubMed ID: 18555933
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting.
    Bergenstal RM, Garrison LP, Wintle M, Blickensderfer A, Wade R, Hou L, Miller LA, Scism-Bacon J, Zagar A, Misurski D, Herman WH.
    Curr Med Res Opin; 2011 Mar 16; 27(3):531-40. PubMed ID: 21219119
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 3.